Other News To Note
• Addex Pharmaceuticals Ltd., of Geneva, reported data showing that orally available candidate GLP1R PAM increased insulin secretion and decreased glycemia in response to glucose in preclinical models of diabetes. In the "db/db" model, in which insulin response to oral glucose in muted, GLP1R PAM (positive allosteric modulator) facilitated an insulin response and better control over blood glucose than vehicle or a marketed drug to treat Type II diabetes.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST